Mechanisms of immunotherapy in allergic rhinitis.
Allergic rhinitis is a common condition, but many people still experience suboptimal control of symptoms despite measures such as allergen avoidance, intra-nasal steroids and antihistamines. Specific immunotherapy (SIT) has been used for many years, but though many studies show clinical efficacy, its mechanism of action is still not clearly understood. Earlier studies showed changes in antibodies and it may be that SIT works through mechanisms that alter the ratio of 'protective' IgG4 to 'pro-allergenic' IgE. Other studies have shown a reduction in eosinophil migration to nasal mucosa as well as a reduction in inflammatory mediator release including basophil histamine release. More recent studies have proposed that SIT works through inhibition of T-helper 2 lymphocytes (Th2) which preferentially produce cytokines that promote allergic responses. SIT may cause a deviation from Th2 to Th1 (T-helper 1 lymphocytes) or may induce T-regulatory cells (T-regs) which inhibit Th2 responses directly or through inhibitory cytokines.